Navigation Links
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Date:5/10/2013

phic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in the last cohort of a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn.

Cautionary Statement Regarding Forward Looking InformationThis news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neural
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
6. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
7. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
8. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
9. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Results from a Phase III clinical trial examining ... reduce the size of melanoma tumors in patients injected ... of Clinical Oncology. , The global, randomized trial ... melanoma, a potentially fatal form of skin cancer. The ... safety and efficacy of the oncolytic virus immunotherapy compared ...
(Date:5/28/2015)... MADISON, N.J. , May 28, 2015  Quest ... provider of diagnostic information services, announced that it is ... Conference in New York.  Steve Rusckowski , the ... goals and five point strategy.  The presentation is scheduled ... Time. The presentation will be webcast live ...
(Date:5/28/2015)... DUBLIN , May 27, 2015 ... addition of Jain PharmaBiotech,s new report "Neuroprotection ... offering. This report describes the role ... and injuries of the nervous system as well ... because many of the underlying mechanisms of damage ...
(Date:5/28/2015)... BioNorth Texas (BioNorthTX), an independent, non-profit ... sciences industry in northern region of Texas, held ... Foundry in Dallas on April 27, 2015. The ... broad spectrum of biotech professionals from the North ... in partnering with key life sciences organizations both ...
Breaking Biology Technology:Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3
... - The next generation of high-performance wireless communication ... at the University of Wisconsin-Madison . , ,But ... the country, pursuing a technology 14 years in the ... diamond and the tiny electromechanical systems into ...
... - Recently, as I sat at lunch sending off ... but reflect on how our professional lives continue to evolve ... ,As the CEO of a company that is driving the ... impressed with how quickly technological change continues to transform and ...
... high-tech startup and spin-off companies are gaining attention ... example of this is Primorigen Biosciences LLC ... for analysis of cellular reprogramming and differentiation. , ... and related products, will use a pair of ...
Cached Biology Technology:Nano-diamond film studied at UW could advance telecommunications 2Nano-diamond film studied at UW could advance telecommunications 3Visions: Rimas Buinevicius, CEO of Sonic Foundry 2Visions: Rimas Buinevicius, CEO of Sonic Foundry 3Wisconsin start up Primorigen Biosciences corrals out-of-state investment 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... the second consecutive year, members of Virginia Tech,s ... in mechanical engineering, directed by professor Pavlos ... the Outstanding Paper Award in fluid mechanics from ... published by the American Institute of Physics. ...
... and Scott Ollinger of the University of New Hampshire,s ... (EOS) have received funding from the National Science Foundation ... for the agency,s new Macrosystems Biology program. The grant ... or so-called carbon "sources" and "sinks" in the long-term ...
... flat Prairie, you,d think a city would provide a good ... in trees and buildings. But researchers at the University of ... far from ideal for these animals. "I was really ... PhD graduate in biological sciences at the University of Calgary ...
Cached Biology News:Virginia Tech mechanical engineers win measurement science best paper award 2UNH researchers receive grant for pioneering carbon cycle model 2UNH researchers receive grant for pioneering carbon cycle model 3Big city holds empty promise for bats 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... of X-ray crystallography services for structure-based ... to its pharmaceutical and biotechnology clients. ... drug-like fragments to the active sites ... scientists to develop novel, high-affinity inhibitors. ...
...
... (AChE) activity. This is a highly sensitive, ... and easy to use assay for AChE ... A series of coupled enzyme reactions translates ... change in luminescence. Inhibitors of AChE are ...
Biology Products: